P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial
Title:
P-231: Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial
Author:
Amatangelo, Michael Cheng, Yiming Pierceall, William van de Donk, Niels W.C.J. Lonial, Sagar Wang, Maria Emerson, Joshua Hong, Kevin Maciag, Paulo Peluso, Teresa Gandhi, Anita Thakurta, Anjan